

# Comvita

## RESEARCH INSIGHTS<sup>#</sup>

### FY19 — Clearing the Cupboard

Comvita (CVT) delivered an FY19 operating loss, as previously signalled, along with a range of goodwill impairments. Operating earnings declined materially following a third consecutive poor honey season, weak sales growth, and a ramp up in opex. CVT is undertaking a CEO search and comprehensive strategic review — with more details expected at its ASM in October. In the interim, while the stock appears prima facie cheap, the past three years have emphasised the high degree of leverage and risk inherent in the business. Until we see any evidence of a turnaround and more insight into the path forward, we would tread carefully.

#### What's changed?

- **Earnings:** EBITDA FY20E/21E lowered -6%.

#### Key take-outs from FY19 result

- **Key markets mixed:** Sales growth over FY19 was mixed in CVT's key markets. ANZ declined -16% as daigou sales slowed due to pricing realignments and Chinese regulatory changes. Europe also lagged as adoption of new MPI standards remains a headwind. Conversely, China performance was solid, and Asia grew strongly with Japan, Korea, and Hong Kong all improving (the Hong Kong protests to impact 1Q20).
- **Another poor honey season pressures margins:** FY19 saw CVT's third poor honey harvest, this time with solid yields but sub-par honey quality due to adverse weather and site overcrowding. This led to a sharp decline in gross margin, down c.-400bps to 37%, and drove another operating loss for its Supply business (of -NZ\$6.9m). The Brand business was also pressured, with a ramp up in marketing spend and costs against a decline in sales, driving operating profit down to an -NZ\$0.7m loss.
- **Gearing remains elevated:** Debt levels have remained high over FY18/19. Thus, gearing metrics deteriorated significantly in FY19 on lower earnings. CVT reiterated that debt is backing an inventory build which is necessary after several poor honey seasons, and that stored honey increases in value over time. However, we lack visibility into the mix of honey held in inventory, and this exacerbates already material leverage in the business.

#### Outlook unclear until strategic review reveal


CVT provided no official FY20 guidance, highlighting only that 4Q19 was behind expectations, and that 1Q20 is tracking ahead of the prior year (albeit 1Q is its seasonally slowest quarter). The outlook is made less clear by the board's strategic review underway and the company's pending new executive hires (currently without a permanent CEO or CFO), which we will receive an update on in October. While we recognise CVT appears cheap on headline metrics, particularly for a brand, the stock requires a significant margin of safety given very high operating and financial leverage, poor historic free cash flow and return on capital, and an uncertain outlook.

#### Investment View

CVT has a leading natural healthcare brand supported by its Manuka Honey operations. It is in the early stages of material strategic change after recent profit pressure, not helped by consecutive weak honey harvests. A streamlined product focus, lowering the apiary risk and greater focus on earnings (rather than revenue) targets makes sense. However, visibility on key targets and the profit trajectory remain limited.

| NZX Code               | CVT              |
|------------------------|------------------|
| Share price            | NZ\$2.75         |
| Issued shares          | 45.2m            |
| Market cap             | NZ\$124m         |
| Average daily turnover | 30.4k (NZ\$133k) |

#### Share Price Performance



| Financials: June | 19A   | 20E  | 21E  | 22E  |
|------------------|-------|------|------|------|
| NPAT* (NZ\$m)    | -7.6  | 8.3  | 12.0 | 15.7 |
| EPS* (NZc)       | -16.7 | 17.9 | 25.9 | 34.0 |
| EPS growth* (%)  | n/a   | n/a  | 44.6 | 31.2 |
| DPS (NZc)        | 0.0   | 0.0  | 6.5  | 8.0  |
| Imputation (%)   | 100   | 100  | 100  | 100  |

| Valuation (x)            | 19A | 20E  | 21E  | 22E |
|--------------------------|-----|------|------|-----|
| EV/EBITDA                | n/a | 9.8  | 8.0  | 6.7 |
| EV/EBIT                  | n/a | 14.5 | 10.9 | 8.7 |
| PE                       | n/a | 15.4 | 10.6 | 8.1 |
| Price / NTA              | 0.9 | 0.9  | 0.8  | n/a |
| Cash dividend yield (%)  | 0.0 | 0.0  | 2.4  | 2.9 |
| Gross dividend yield (%) | 0.0 | 0.0  | 3.3  | 4.0 |

\*Historic and forecast numbers based on underlying profits

#### Chelsea Leadbetter, CFA

chelsea.leadbetter@forsythbarr.co.nz

+64 4 495 5262

#### Matt Dunn

matt.dunn@forsythbarr.co.nz

+64 9 368 0103

<sup>#</sup>Forsyth Barr RESEARCH INSIGHTS targets selected smaller cap stocks or those under transitional coverage and focuses on qualitative rather than quantitative assessments. We do not provide investment ratings or target prices on these stocks.

**Comvita (CVT)**

Priced as at 23 Aug 2019: NZ\$2.75

June year end

**Research Insights**

Forsyth Barr Research Insights focuses on qualitative rather than quantitative assessments of an equity investment.

We do not provide valuation, target prices or investment ratings for companies in the Research Insights series. It is targeted at selected smaller cap stocks with typically higher risk attributes, or those under transitional coverage.

Our earnings and cashflow forecasts, together with key valuation and ratios provided on this page should assist investors in determining the relative valuation merits of the company.

**Valuation Ratios**

|                          | 2018A | 2019A | 2020E | 2021E | 2022E |
|--------------------------|-------|-------|-------|-------|-------|
| EV/EBITDA (x)            | 11.5  | n/a   | 9.8   | 8.0   | 6.7   |
| EV/EBIT (x)              | 19.2  | n/a   | 14.5  | 10.9  | 8.7   |
| PE (x)                   | 13.4  | n/a   | 15.4  | 10.6  | 8.1   |
| Price/NTA (x)            | 0.8   | 0.9   | 0.9   | 0.8   | 0.7   |
| Free cash flow yield (%) | -22.3 | 3.6   | 1.7   | 8.1   | 6.8   |
| Net dividend yield (%)   | 2.2   | 0.0   | 0.0   | 2.4   | 2.9   |
| Gross dividend yield (%) | 3.0   | 0.0   | 0.0   | 3.3   | 4.0   |
| Imputation (%)           | 100   | 100   | 100   | 100   | 100   |
| Pay-out ratio (%)        | 29    | 0     | 0     | 25    | 24    |

**Capital Structure**

|                           | 2018A | 2019A | 2020E | 2021E | 2022E |
|---------------------------|-------|-------|-------|-------|-------|
| Interest cover EBIT (x)   | 2.9   | n/a   | 3.7   | 5.7   | 7.8   |
| Interest cover EBITDA (x) | 4.8   | n/a   | 5.5   | 7.8   | 10.1  |
| Net debt/ND+E (%)         | 32.6  | 33.9  | 32.3  | 28.7  | 26.2  |
| Net debt/EBITDA (x)       | 5.9   | n/a   | 4.2   | 3.1   | 2.4   |

**Profit and Loss Account (NZ\$m)**

|                               | 2018A       | 2019A         | 2020E       | 2021E       | 2022E       |
|-------------------------------|-------------|---------------|-------------|-------------|-------------|
| Sales revenue                 | 178.5       | 171.1         | 217.8       | 233.1       | 247.1       |
| <b>Normalised EBITDA</b>      | <b>15.5</b> | <b>(2.0)</b>  | <b>20.5</b> | <b>25.0</b> | <b>29.8</b> |
| Depreciation and amortisation | (6.2)       | (6.4)         | (6.6)       | (6.7)       | (6.7)       |
| <b>Normalised EBIT</b>        | <b>9.3</b>  | <b>(8.5)</b>  | <b>13.9</b> | <b>18.3</b> | <b>23.1</b> |
| Net interest                  | (3.2)       | (6.1)         | (3.8)       | (3.2)       | (3.0)       |
| Associate income              | 1.2         | (2.0)         | 1.0         | 1.1         | 1.2         |
| Tax                           | (2.9)       | 3.4           | (2.8)       | (4.2)       | (5.6)       |
| Minority interests            | -           | -             | -           | -           | -           |
| <b>Normalised NPAT</b>        | <b>9.3</b>  | <b>(7.6)</b>  | <b>8.3</b>  | <b>12.0</b> | <b>15.7</b> |
| Abnormals/other               | (3.8)       | 14.6          | -           | -           | -           |
| <b>Reported NPAT</b>          | <b>8.2</b>  | <b>(27.7)</b> | <b>8.3</b>  | <b>12.0</b> | <b>15.7</b> |
| Normalised EPS (cps)          | 20.6        | (16.7)        | 17.9        | 25.9        | 34.0        |
| DPS (cps)                     | 6.0         | -             | -           | 6.5         | 8.0         |

**Growth Rates**

|                     | 2018A | 2019A  | 2020E | 2021E | 2022E |
|---------------------|-------|--------|-------|-------|-------|
| Revenue (%)         | 14.5  | -4.1   | 27.3  | 7.1   | 6.0   |
| EBITDA (%)          | 87.6  | n/a    | n/a   | 21.9  | 19.2  |
| EBIT (%)            | >100  | n/a    | n/a   | 31.9  | 26.2  |
| Normalised NPAT (%) | >100  | n/a    | n/a   | 44.6  | 31.2  |
| Normalised EPS (%)  | >100  | n/a    | n/a   | 44.6  | 31.2  |
| DPS (%)             | >100  | -100.0 | n/a   | n/a   | 23.6  |

**Key Ratios**

|                              | 2018A | 2019A | 2020E | 2021E | 2022E |
|------------------------------|-------|-------|-------|-------|-------|
| Return on assets (%)         | 2.9   | -2.7  | 4.3   | 5.6   | 6.9   |
| Return on equity (%)         | 4.9   | -4.4  | 4.6   | 6.2   | 7.7   |
| Return on funds employed (%) | 1.3   | -2.9  | 3.4   | 4.6   | 5.8   |
| EBITDA margin (%)            | 8.7   | -1.2  | 9.4   | 10.7  | 12.1  |
| EBIT margin (%)              | 5.2   | -4.9  | 6.4   | 7.9   | 9.4   |
| Capex to sales (%)           | 3.1   | 9.7   | 2.0   | 1.0   | 1.0   |
| Capex to depn + amort (%)    | 90    | 260   | 66    | 35    | 37    |

**Operating Performance**

|                      | 2018A      | 2019A      | 2020E      | 2021E      | 2022E      |
|----------------------|------------|------------|------------|------------|------------|
| <b>Revenue</b>       |            |            |            |            |            |
| New Zealand          | 37         | 34         | 33         | 32         | 32         |
| Australia            | 45         | 36         | 35         | 34         | 33         |
| China                | 12         | 27         | 61         | 71         | 78         |
| Asia                 | 37         | 41         | 45         | 51         | 57         |
| North America        | 27         | 13         | 22         | 23         | 24         |
| Europe               | 9          | 6          | 7          | 7          | 7          |
| Other                | 12         | 14         | 14         | 15         | 16         |
| <b>Total revenue</b> | <b>178</b> | <b>171</b> | <b>218</b> | <b>233</b> | <b>247</b> |

**Cash Flow (NZ\$m)**

|  | 2018A         | 2019A        | 2020E        | 2021E        | 2022E        |
|--|---------------|--------------|--------------|--------------|--------------|
| <b>EBITDA</b>                          | <b>15.5</b>   | <b>(2.0)</b> | <b>20.5</b>  | <b>25.0</b>  | <b>29.8</b>  |
| Working capital change                 | (37.1)        | 17.3         | (7.5)        | (5.2)        | (10.3)       |
| Interest & tax paid                    | (5.5)         | (6.3)        | (6.6)        | (7.4)        | (8.6)        |
| Other                                  | 5.0           | 12.1         | -            | -            | -            |
| <b>Operating cash flow</b>             | <b>(22.1)</b> | <b>21.1</b>  | <b>6.5</b>   | <b>12.4</b>  | <b>10.9</b>  |
| Capital expenditure                    | (5.5)         | (16.7)       | (4.4)        | (2.3)        | (2.5)        |
| (Acquisitions)/divestments             | 0.5           | 0.4          | -            | -            | -            |
| Other                                  | 0.2           | (0.1)        | -            | -            | -            |
| <b>Funding available/(required)</b>    | <b>(27.0)</b> | <b>4.7</b>   | <b>2.1</b>   | <b>10.0</b>  | <b>8.4</b>   |
| Dividends paid                         | (1.8)         | (0.9)        | -            | (0.9)        | (3.5)        |
| Equity raised/(returned)               | 1.0           | 0.6          | -            | -            | -            |
| <b>Increase/(decrease) in net debt</b> | <b>27.8</b>   | <b>(4.4)</b> | <b>(2.1)</b> | <b>(9.1)</b> | <b>(5.0)</b> |

**Revenue % chg**

|                      | 2018A       | 2019A        | 2020E       | 2021E      | 2022E      |
|----------------------|-------------|--------------|-------------|------------|------------|
| New Zealand          | 11.9        | (8.3)        | (3.0)       | (2.0)      | (2.0)      |
| Australia            | 43.0        | (21.8)       | (3.0)       | (2.0)      | (2.0)      |
| China                | (57.8)      | 122.4        | -           | -          | -          |
| Asia                 | 13.8        | 12.1         | 10.0        | 12.0       | 12.0       |
| North America        | 597.7       | (50.2)       | 65.4        | 5.0        | 5.0        |
| Europe               | 17.2        | (28.3)       | 10.0        | 3.0        | 3.0        |
| Other                | (38.4)      | 19.8         | 5.0         | 5.0        | 5.0        |
| <b>Total revenue</b> | <b>14.5</b> | <b>(4.1)</b> | <b>27.3</b> | <b>7.1</b> | <b>6.0</b> |

**Operating expenses**

|                           | 2018A       | 2019A       | 2020E       | 2021E       | 2022E       |
|---------------------------|-------------|-------------|-------------|-------------|-------------|
| Selling and marketing     | (38)        | (44)        | (46)        | (48)        | (50)        |
| Administrative            | (16)        | (20)        | (21)        | (22)        | (22)        |
| Distribution              | (8)         | (8)         | (9)         | (9)         | (9)         |
| Research and development  | (3)         | (2)         | (2)         | (2)         | (2)         |
| <b>Operating expenses</b> | <b>(65)</b> | <b>(74)</b> | <b>(77)</b> | <b>(81)</b> | <b>(83)</b> |

**Balance Sheet (NZ\$m)**

|                               | 2018A        | 2019A        | 2020E        | 2021E        | 2022E        |
|-------------------------------|--------------|--------------|--------------|--------------|--------------|
| Working capital               | 149.4        | 133.6        | 136.5        | 143.4        | 152.6        |
| Fixed assets                  | 47.5         | 56.9         | 55.9         | 53.3         | 50.8         |
| Intangibles                   | 33.4         | 38.7         | 37.4         | 35.7         | 33.9         |
| Other assets                  | 60.4         | 41.7         | 47.2         | 46.6         | 49.0         |
| <b>Total funds employed</b>   | <b>290.7</b> | <b>270.9</b> | <b>277.0</b> | <b>279.0</b> | <b>286.3</b> |
| Net debt/(cash)               | 91.8         | 88.9         | 86.8         | 77.7         | 72.7         |
| Other non current liabilities | 9.2          | 8.6          | 8.6          | 8.6          | 8.6          |
| Shareholder's funds           | 189.7        | 173.4        | 181.6        | 192.7        | 205.0        |
| Minority interests            | -            | -            | -            | -            | -            |
| <b>Total funding sources</b>  | <b>290.7</b> | <b>270.9</b> | <b>277.0</b> | <b>279.0</b> | <b>286.3</b> |

\* Forsyth Barr target prices reflect valuation rolled forward at cost of equity less the next 12-months dividend

## FY19 result analysis

Figure 1. FY19 result analysis

| NZ\$m                                  | FY18          | FY19          | % chg         |  |
|--|---------------|---------------|---------------|--|
| <b>Revenue</b>                         |               |               |               |  |
| Australia & NZ                         | 82.6          | 66.6          | -15.7%        | Daigou sales impacted by regulatory changes and strategic pricing realignment  |
| China                                  | 12.1          | 26.9          | 122.4%        | Consolidated China business sales +14% to NZ\$52m (prior NZ\$46m)  |
| Asia                                   | 36.8          | 41.3          | 12.1%         | Strong growth in Japan, Korea & Hong Kong. Expect impact from Hong Kong protests in 1Q20   |
| North America                          | 26.8          | 13.4          | -50.2%        | Due to Costco inventory build in prior year and delay in recommencing purchasing   |
| Europe                                 | 8.7           | 6.2           | -28.3%        | Weak year; changes have been made which should see improvements in FY20  |
| Other                                  | 11.5          | 13.8          | 19.8%         |  |
| <b>Total revenue</b>                   | <b>178.5</b>  | <b>171.1</b>  | <b>-4.1%</b>  |  |
| Cost of sales                          | (105.3)       | (107.3)       | 1.9%          |  |
| <b>Gross profit</b>                    | <b>73.2</b>   | <b>63.8</b>   | <b>-12.9%</b> | <b>Gross margin 37.3% (pcp 41.0%) – third consecutive poor honey season with lower quality production (poor weather and site overcrowding) &amp; market pressure</b> |
| Other income                           | 1.1           | 1.3           | 17.9%         |  |
| <b>Expenses</b>                        |               |               |               |  |
| Selling and marketing                  | (37.9)        | (43.7)        | 15.5%         | Planned step up in marketing spend   |
| Administration                         | (16.0)        | (19.7)        | 23.7%         | Marked step-up, with limited visibility on drivers   |
| Distribution                           | (8.1)         | (8.4)         | 3.7%          |  |
| R&D                                    | (3.1)         | (1.7)         | -45.8%        |  |
| <b>Total expenses</b>                  | <b>(65.0)</b> | <b>(73.5)</b> | <b>13.1%</b>  | <b>Cost acceleration materially outpaced revenue, with margins squeezed</b>  |
| <b>EBIT (pre abnormals)</b>            | <b>9.3</b>    | <b>(8.5)</b>  | <b>na</b>     |  |
| Abnormal items                         | 3.8           | (14.6)        | na            | NZ\$19.8m goodwill impairment outweighed gain on sale of China JV during consolidation   |
| <b>EBIT</b>                            | <b>13.1</b>   | <b>(23.0)</b> | <b>na</b>     |  |
| Net financing cost                     | (3.2)         | (6.1)         | 92.2%         | FX loss vs FX gain in pcp. Higher average net debt to support inventory build  |
| <b>Net profit before tax</b>           | <b>9.9</b>    | <b>(29.2)</b> | <b>na</b>     |  |
| Tax                                    | (2.9)         | 3.4           | na            |  |
| <b>Net profit after tax</b>            | <b>7.0</b>    | <b>(25.8)</b> | <b>na</b>     |  |
| Equity acc'd earnings                  | 1.9           | 0.4           | -76.7%        |  |
| Impairment of equity acc'd investments | (0.7)         | (2.4)         | na            | Primarily NZ\$2.3m impairment of Putake Group due to poor honey season and MPI definition change   |
| <b>Reported NPAT</b>                   | <b>8.2</b>    | <b>(27.7)</b> | <b>na</b>     |  |
| <b>Underlying NPAT</b>                 | <b>9.3</b>    | <b>(7.6)</b>  | <b>na</b>     | <b>Split between (1) Brand business NZ\$(0.7)m vs. FY18 NZ\$15.5m, (2) Supply business NZ\$(6.9m) vs. FY18 NZ\$(6.2)m</b>  |
| Underlying EPS (cps)                   | 13.7          | (20.4)        | na            |  |
| Dividend (cps)                         | 6.0           | 0.0           | na            | As expected given a weak FY19 result and elevated gearing (net debt NZ\$89m)   |

Source: Company reports, Forsyth Barr analysis

## Earnings revisions

We make small downgrades to our near-term revenue forecasts and account for the China JV consolidation. Operating leverage and higher depreciation & interest drives a more material impact to earnings.

We have also lowered our dividend expectations, given CVT's elevated gearing position and while the board works through material strategic change.

Figure 2. Earnings revisions (NZ\$m)

|                        | FY20E       |             |               | FY21E       |             |               | FY22E       |
|------------------------|-------------|-------------|---------------|-------------|-------------|---------------|-------------|
|                        | Old         | New         | % chg         | Old         | New         | % chg         | New         |
| Revenue                | 223.5       | 217.8       | -2.6%         | 241.0       | 233.1       | -3.3%         | 247.1       |
| <b>EBITDA</b>          | <b>21.9</b> | <b>20.5</b> | <b>-6.0%</b>  | <b>26.7</b> | <b>25.0</b> | <b>-6.1%</b>  | <b>29.8</b> |
| <b>Normalised NPAT</b> | <b>10.3</b> | <b>8.3</b>  | <b>-19.1%</b> | <b>14.5</b> | <b>12.0</b> | <b>-17.1%</b> | <b>15.7</b> |
| Adjusted EPS (cps)     | 22.7        | 17.9        | -20.9%        | 32.0        | 25.9        | -19.0%        | 34.0        |
| Dividend (cps)         | 4.5         | 0.0         | na            | 8.0         | 6.5         | -19.2%        | 8.0         |

Source: Forsyth Barr analysis

## Investment summary

Comvita (CVT) has a leading natural healthcare brand supported by its Manuka Honey apiary operations. Recent results have seen considerable challenges, not helped by three consecutive poor harvests. This has led to a suite of strategic changes which are still in their infancy. This, combined with high operating and financial leverage, makes CVT a high risk investment. We look for any early signs of progress and greater clarity on the medium-term profit trajectory / opportunity.

### Earnings and cash flow outlook

- **Key earnings drivers:** Profit results are driven by (1) Honey harvest — a key driver of supply and quality (which impacts honey grade and thereby price achievement), (2) sales performance across key markets (China, US) and (3) gross margins.
- **Earnings volatility:** Honey supply volatility, due to climatic conditions, has significantly impacted earnings historically. Work has been undertaken to lower the risk for future results, but volatility has remained evident through FY19. New disclosure from FY18 helps to separate apiary earnings ('Supply') and the branded business ('Brand') for investors to more appropriately value CVT.

### Business quality

- **Revised strategy:** CVT is in the early stages of strategic changes, with a more streamlined focus on its Manuka Honey and Propolis based products. Detail remains scarce and revised targets / benchmarks have yet to be provided, but we understand it will be more profit-orientated rather than revenue-based.

### Financial structure

- **Inventory and gearing:** CVT has elevated gearing metrics following a debt-funded inventory build over FY18 and FY19. While inventory levels cover net debt, it adds financial leverage and risk to an already volatile business.


### Risks factors

- **Food safety, product quality:** Critical for CVT to maintain its quality reputation and brand value which enables a premium price.
- **Fraud:** Fraudulent Manuka Honey products such as those highlighted in the UK recently have the potential to erode Manuka Honey brand value.

### Company description


Comvita (CVT) is a vertically integrated natural health product company. It specialises in honey-based products, with a particular focus on Manuka honey. CVT generates sales globally, with Australia, Asia, UK/Europe, and the US amongst key geographies. The company owns or has supply contracts with over 30% of global Manuka honey supply.

Figure 3. Revenue by geography (FY19)



Source: Company reports, Forsyth Barr analysis

Figure 4. Margins over time



Source: Company reports, Forsyth Barr analysis

**Figure 5. Substantial Shareholders**

| Shareholder         | Latest Holding |
|---------------------|----------------|
| Li Wang             | 16.8%          |
| Kauri NZ Investment | 10.5%          |
| China Resources     | 10.1%          |
| Hamish Coleman      | 5.8%           |


Source: NZX, Forsyth Barr analysis, NOTE: based on SSH notices only

**Figure 6. International Compco's**


| Company   | Code   | Price     | Mkt Cap    | PE           | EV/EBITDA    | EV/EBIT      | Cash D/Yld   |
|---|--------|-----------|------------|--------------|--------------|--------------|--------------|
| <i>(metrics re-weighted to reflect CVT's balance date - June)</i> |        |           |            |              |              |              |              |
| Comvita   | CVT NZ | NZ\$2.75  | NZ\$124    | 15.4x        | 10.6x        | 10.4x        | 8.5x         |
| The a2 Milk Company *   | ATM NZ | NZ\$14.75 | NZ\$10,842 | 32.2x        | 24.2x        | 21.4x        | 16.1x        |
| Blackmores  | BKL AT | A\$67.44  | A\$1,171   | 21.8x        | 18.7x        | 13.2x        | 11.4x        |
| Scales *  | SCL NZ | NZ\$4.64  | NZ\$657    | 18.1x        | 16.8x        | 12.7x        | 11.9x        |
| Delegat Group *   | DGL NZ | NZ\$11.72 | NZ\$1,185  | 23.0x        | 19.7x        | 14.5x        | 12.8x        |
| Sanford *   | SAN NZ | NZ\$6.87  | NZ\$642    | 13.7x        | 11.6x        | 8.0x         | 6.9x         |
| New Zealand King Salmon *   | NZK NZ | NZ\$2.16  | NZ\$299    | 21.9x        | 21.7x        | 11.7x        | 10.9x        |
| <b>Compco Average:</b>  |        |           |            | <b>21.8x</b> | <b>18.8x</b> | <b>13.6x</b> | <b>11.7x</b> |
| <b>CVT Relative:</b>  |        |           |            | <b>-29%</b>  | <b>-43%</b>  | <b>-24%</b>  | <b>-27%</b>  |
|   |        |           |            |              |              | <b>-4%</b>   | <b>-16%</b>  |

EV = Current Market Cap + Actual Net Debt

Source: \*Forsyth Barr analysis, Bloomberg Consensus, Compco metrics re-weighted to reflect headline (CVT) companies fiscal year end

**Figure 7. Consensus EPS Momentum**


Source: Forsyth Barr analysis

**Figure 8. 12 Month Forward PE**


Source: Forsyth Barr analysis

**Not personalised financial advice:** The recommendations and opinions in this publication do not take into account your personal financial situation or investment goals. The financial products referred to in this publication may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Advisor. The value of financial products may go up and down and investors may not get back the full (or any) amount invested. Past performance is not necessarily indicative of future performance. Disclosure statements for Forsyth Barr Investment Advisors are available on request and free of charge. **Disclosure:** Forsyth Barr Limited and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) investment banking or other services to, the issuer of those financial products (and may receive fees for so acting). Forsyth Barr is not a registered bank within the meaning of the Reserve Bank of New Zealand Act 1989. Forsyth Barr may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Forsyth Barr confirms no inducement has been accepted from the researched entity, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. **Analyst Disclosure Statement:** In preparing this publication the analyst(s) may or may not have a threshold interest in the financial products referred to in this publication. For these purposes a threshold interest is defined as being a holder of more than \$50,000 in value or 1% of the financial products on issue, whichever is the lesser. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the entity being researched. **Disclaimer:** This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. Forsyth Barr does not make any representation or warranty (express or implied) that the information in this publication is accurate or complete, and, to the maximum extent permitted by law, excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice. Any analyses or valuations will typically be based on numerous assumptions; different assumptions may yield materially different results. Nothing in this publication should be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from doing so, or to engage in any other transaction. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction. **Terms of use:** Copyright Forsyth Barr Limited. You may not redistribute, copy, revise, amend, create a derivative work from, extract data from, or otherwise commercially exploit this publication in any way. By accessing this publication via an electronic platform, you agree that the platform provider may provide Forsyth Barr with information on your readership of the publications available through that platform.